1Kayikcioglu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer, 2001, 11(6):466-470.
2Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotheray for advanced ovarian cancer:, long-term survival. Gynecol Onco1,1999, 72(1): 93-99.
3Hatae M, Onishi Y, Nakamura T, et al. The role of surgery for advanced epithelial ovarian cancer. Gan To Kagaku Ryoho, 1998, 25(2): 201-207.
4Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovaian carcinoma:a retrospective case-control study. Eur J Gynecol Oncol, 2002,23(5):405-410.
5Kuhn W, Ratko S,Spathe K, et al. Neoadjuvant chemotherapy following tumor debulking prolongs survicval for patients with poor prognosis in International Federation of Gynecol and Obstetrics Stage Ⅲc ovarian cancinoma. Cancer, 2001, 92(10): 2589-2591.
6Fanfani F, Ferrandina G, Corrado G, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage Ⅲc ovarian cancer patients. Int J Gynecol Cancer, 2003,13[Suppl 1]:37.
7Mazzeo F, Berliere M, Kerger J, et al. Neoadjuvant chemotherapy followed by stagoT and adjuvant chemotherapy in patients with primarily uruesectable,advanced-stage varian cancer. Gynecol Onco12003,90(1):163-169.
8Vergote IB, De-Wever I, Decloedt J, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol, 2000, 27[Suool 71:31-36.
9Toumigand C, Louvet C, Molitor JL, et al. Intravenous ehemotherapy,early debulking surgery, and consolidation intrapefitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol, 2001, 83(2): 198-204.
10Shimizu Y. Recent advances in inrtaarterial chemotherapy in gynecologic malignancy. Gan To Kagaku Ryoho, 2002,29(2): 189-196.
4Boente MP,Chids,HosKins WJ.The roles of surgery in the managerment of ovarian cancer primary and interval cytoreductive surgery[J].Semin in Oncol,1998,25:326.
5Kuhn W,Rutke S,Spathe K,et al.Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in international Federation of Gynecology and Obstetrics StageⅢ ovarian carcinoma[J].Cancer,2001,92(12):2585.
